Inve India ▾

Amanta Healthcare share price & results

Amanta Healthcare Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Gujarat-based sterile-liquids pharma manufacturer of IV fluids (LVP/SVP), diluents, ophthalmic, respiratory and irrigation solutions, exported to 120+ countries

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue68.8 ₹ crore+5.3% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin21.1 %−1.7 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit3.3 ₹ crore−5.7% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity9.68 %−2.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-11.11 %−20.6 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)7.08 %+6.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

1 of 2 judged targets kept · 15 open · verdicts reflect calls analysed to Q1 FY27.

Amanta Healthcare Limited management guidance track record on Inve: 17 targets tracked across analysed earnings calls (1 achieved, 1 missed, 15 open).

TargetOriginal wordingSaidLatest callVerdict
Solar Plant Cost Savings₹9 crores annual EBITDA level savings from Q1 FY27
Call transcript, Q3 FY26 · 11 Feb 2026		Q3 FY26Q1 FY27:The 10.8 MW captive solar power project was commissioned in June 2026. Management confirmed it is projected to save ₹75 lakhs per month, achieving the annualized target.
Call transcript, Q1 FY27 · 6 Aug 2026		Achieved
Debt RefinancingReplace around ₹30 crores to ₹40 crores of debt with lower interest rate in next six months
Call transcript, Q4 FY26 · 21 May 2026		Q4 FY26Q1 FY27:No specific update was provided on the status of this refinancing activity targeted for H1 FY27 (ending Sep 2026).
Call transcript, Q1 FY27 · 6 Aug 2026		Ghosted
LVP SteriPort Capacity Commercialization12 crore bottles per annum by April 2026
Call transcript, Q3 FY26 · 11 Feb 2026		Q3 FY26Q1 FY27:Commissioning delayed from Q1 to Q2 due to civil construction issues. Commercial production now anticipated by the last week of August 2026.
Call transcript, Q1 FY27 · 6 Aug 2026		Delayed

Source: Inve Guidance Tracker for Amanta Healthcare Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of Amanta Healthcare Limited's 17 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 14 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹157.74 −5.46% · −₹9.11

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +26.1% 1Y

₹100₹150₹200Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q3 FY26 — 11 Feb 2026Q4 FY26 — 21 May 2026Q1 FY27 — 6 Aug 2026

1Y: ₹125.1 on 24 Oct 2025 → ₹157.74. High ₹207.08 (7 Oct 2026), low ₹95.03 (17 Mar 2026).

Previous close
₹166.85
Market cap
₹648 Cr
52-week range
₹95.03 – ₹207.08
One year
+26.94%
Price to earnings (TTM to Jun 2026)
42.24×
Return on equity (TTM to Jun 2026)
9.68%

Overview

Symbol
NSE:AMANTA
Exchange
NSE
Currency
INR

What Amanta Healthcare Limited does

Based on the company's own presentations, annual report and earnings calls.

Amanta Healthcare manufactures sterile liquid pharmaceuticals across six therapeutic segments: IV fluids (Large Volume Parenterals), Small Volume Parenterals, diluents & injectables, ophthalmic solutions, respiratory solutions and irrigation solutions. It uses Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch-Blow Moulding (ISBM) technologies, including its proprietary SteriPort two-port IV bottle platform, to produce sterile liquids with minimal human contact. The company sells domestically under its own brand names through a distributor network and exports formulations to emerging and semi-regulated international markets under product registrations in many jurisdictions.

Segments

  • Fluid Therapy (IV Fluids)
  • Formulations (Injectables/Ophthalmic/Respiratory)
  • Diluents & Injectables
  • Ophthalmic Solutions
  • Respiratory Solutions
  • Irrigation Solutions
  • SteriPort
Manufacturing facility
1 WHO-GMP facility spanning 66,852 sq. meters (Hariyala, Kheda, Gujarat)
Production lines
7 (LVP 4 lines, SVP 3 lines)
Installed capacity - LVP (incl. SteriPort)
12.28 crore bottles/yr
Installed capacity - SVP
20.91 crore units/yr
Product portfolio
47 products
Distributors & stockists
320+
Headquarters Ahmedabad, Gujarat, IndiaEmployees 506 (FY26) Company website

How the price took the results

close before → close after

Q1 FY27
−2.0%
6 Aug
Q4 FY26
−0.1%
21 May
Q3 FY26
+2.1%
11 Feb

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Amanta Healthcare Limited

Free account: one company. Everything above stays public.

Write why you follow Amanta Healthcare Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Amanta Healthcare Limited

Guides on how to read this kind of business and the numbers that matter.